Tortugas Neuroscience Announces Appointment of Ramzi Benamar as Chief Financial Officer
Tortugas Neuroscience (“Tortugas”), a clinical-stage biotech company developing medicines for central nervous system (CNS) disorders, today announced the appointment of Ramzi Benamar as Chief Financial Officer (CFO). Benamar is a biotechnology executive with experience in capital formation, corporate strategy, M&A, operational scaling, and commercial launch preparation. He has participated in and led these activities across multiple life sciences companies.
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
Tortugas Neuroscience (“Tortugas”), a clinical-stage central nervous system (CNS)-focused biotech company developing medicines with clinically validated mechanisms of action in indications with both substantial patient populations and high unmet need, today announced the appointment of Jim Frates to its Board of Directors and as Chair of the Audit Committee. A highly experienced biopharmaceutical leader who has served as chief financial officer (CFO) for multiple public and private biotechnology companies, Frates currently serves as CFO of Amylyx Pharmaceuticals (Nasdaq: AMLX).
Tortugas Neuroscience Launches with $106 Million to Advance Clinical Stage Pipeline Targeting New and Major Neurology and Neuropsychiatric Disorders
Tortugas Neuroscience (“Tortugas”), a neurology-focused biotech company developing novel medicines with derisked mechanisms of actions, for large and well-defined indications, today announces $106 million in Seed and Series A financings. The funding will support ongoing research and development initiatives, including the completion of Phase 2 clinical trials for its two lead candidates.
